Puma Biotechnology, Inc.
PBYI
$3.01
-$0.03-0.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.12% | -18.15% | 43.53% | -13.72% | -17.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.12% | -18.15% | 43.53% | -13.72% | -17.07% |
| Cost of Revenue | -1.60% | -42.77% | 119.04% | -10.11% | -18.84% |
| Gross Profit | 7.30% | -5.64% | 20.11% | -14.72% | -16.48% |
| SG&A Expenses | -19.06% | -15.02% | -26.24% | 2.08% | -3.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.77% | -19.46% | 23.00% | -0.83% | -4.84% |
| Operating Income | 273.29% | -13.34% | 157.18% | -144.54% | -152.67% |
| Income Before Tax | 171.10% | -4.42% | 242.95% | -279.46% | -396.83% |
| Income Tax Expenses | 33.18% | -1,418.47% | 36.62% | 102.14% | 49.66% |
| Earnings from Continuing Operations | 161.77% | 57.36% | 250.53% | -313.03% | -443.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 161.77% | 57.36% | 250.53% | -313.03% | -443.68% |
| EBIT | 273.29% | -13.34% | 157.18% | -144.54% | -152.67% |
| EBITDA | 1,033.78% | -11.50% | 117.76% | -90.62% | -91.74% |
| EPS Basic | 160.06% | 52.58% | 239.84% | -306.15% | -433.00% |
| Normalized Basic EPS | 169.13% | -11.63% | 232.66% | -273.79% | -387.92% |
| EPS Diluted | 160.00% | 58.48% | 241.67% | -306.15% | -433.33% |
| Normalized Diluted EPS | 168.62% | -11.39% | 233.63% | -275.49% | -390.73% |
| Average Basic Shares Outstanding | 2.92% | 3.14% | 3.13% | 3.28% | 3.33% |
| Average Diluted Shares Outstanding | 3.56% | 2.85% | 2.83% | 2.31% | 2.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |